Clinical Trial: Autologous Skin Cell Suspension (RECELL(R)) for Accelerated Healing of Split-Thickness Skin Graft Donor Sites: A Randomized, Intra-Patient (Split-Site) Controlled Trial

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07888166) titled 'Autologous Skin Cell Suspension (RECELL(R)) for Accelerated Healing of Split-Thickness Skin Graft Donor Sites: A Randomized, Intra-Patient (Split-Site) Controlled Trial' on Oct. 14.

Brief Summary: This study evaluates whether applying RECELL(R) autologous skin cell suspension (ASCS) to one half of a split-thickness skin graft (STSG) donor site accelerates re-epithelialization and improves long-term scar quality compared with the untreated half of the same donor site. Using a prospective, randomized, intra-patient (split-site) controlled design, each participant's donor site is divided into two contiguous, comparable halves at the ti...